- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Efficacy End Points For PNH Treatment
Dr Haumschild continues leading an expert discussion surrounding key strategies and pain points in PNH treatment.
EP: 1.PNH Overview and Pathophysiology
EP: 2.Intravascular and Extravascular Hemolysis MoA in PNH
EP: 3.Utilizing Health Information Technology to Bridge Gaps in PNH Treatment Programming
EP: 4.Key Treatment Considerations for Patients Diagnosed With PNH
EP: 5.Complement System Role in PNH Treatment Approach
EP: 6.Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management
EP: 7.Efficacy End Points For PNH Treatment
EP: 8.Efficacy and Safety Trials Results of Complement Inhibitors
EP: 9.Treatment Adherence and Cost Considerations Surrounding Various Routes of PNH Treatment Administration
EP: 10.Investigational Therapies Paving New PNH Treatment Pathways
EP: 11.Key Financial Factors Associated With Typical PNH Treatment Journey
EP: 12.Navigating Transfusion Requirements in PNH Treatment
EP: 13.Considerations for Managing PNH Treatment Complications
EP: 14.Infection Risk Management Counseling For Patients Receiving Treatment for PNH
EP: 15.Ensuring PNH Treatment Access and Adherence to Therapies
EP: 16.Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway
Video content above is prompted by the following:
- Please describe the significance of the different efficacy end points explored for paroxysmal nocturnal hemoglobinuria treatments (eg, lactate dehydrogenase levels, hemoglobin concentrations, absolute reticulocyte count (ARC) levels, transfusion avoidance, Functional Assessment of Chronic Illness Therapy–Fatigue).
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
